Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | L3MBTL1 | Q9Y468 | 3/20 | 1.00 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.76 |
| ▸ | PKM | P14618 | 1/20 | 0.74 |
| ▸ | RAPGEF4 | Q8WZA2 | 2/20 | 0.71 |
| ▸ | HDAC3 | O15379 | 2/20 | 0.59 |
| ▸ | HDAC4 | P56524 | 2/20 | 0.59 |
| ▸ | HDAC1 | Q13547 | 2/20 | 0.59 |
| ▸ | HDAC7 | Q8WUI4 | 2/20 | 0.59 |
| ▸ | HDAC2 | Q92769 | 2/20 | 0.59 |
| ▸ | HDAC10 | Q969S8 | 2/20 | 0.59 |
| ▸ | HDAC11 | Q96DB2 | 2/20 | 0.59 |
| ▸ | HDAC8 | Q9BY41 | 2/20 | 0.59 |
| ▸ | HDAC6 | Q9UBN7 | 2/20 | 0.59 |
| ▸ | HDAC9 | Q9UKV0 | 2/20 | 0.59 |
| ▸ | HDAC5 | Q9UQL6 | 2/20 | 0.59 |
| ▸ | ENPP3 | O14638 | 1/20 | 0.56 |
| ▸ | HTT | P42858 | 3/20 | 0.48 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.48 |
| ▸ | LMNA | P02545 | 2/20 | 0.48 |
| ▸ | MAPT | P10636 | 2/20 | 0.48 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL30365350 | 1.00 | L3MBTL1 (1.00) | L3MBTL1CYP2C19PKMRAPGEF4HDAC3 | |
| SCHEMBL4532804 | 1.00 | L3MBTL1 (1.00) | L3MBTL1CYP2C19PKMRAPGEF4HDAC3 | |
| SCHEMBL27795367 | 0.87 | L3MBTL1 (0.76) | L3MBTL1CYP2C19PKMRAPGEF4HDAC3 | |
| SCHEMBL1773294 | 0.86 | CYP2C19 (1.00) | L3MBTL1CYP2C19PKMRAPGEF4HDAC3 | |
| SCHEMBL16516428 | 0.86 | L3MBTL1 (0.75) | L3MBTL1CYP2C19PKMRAPGEF4HDAC3 | |
| SCHEMBL20549621 | 0.85 | CYP2C19 (0.76) | L3MBTL1CYP2C19PKMRAPGEF4HDAC3 | |
| SCHEMBL3507507 | 0.85 | PKM (1.00) | L3MBTL1CYP2C19PKMRAPGEF4HDAC3 | |
| SCHEMBL15175383 | 0.83 | RAPGEF4 (1.00) | L3MBTL1CYP2C19PKMRAPGEF4HDAC3 | |
| SCHEMBL27942418 | 0.82 | L3MBTL1 (0.68) | L3MBTL1CYP2C19PKMRAPGEF4HDAC3 | |
| SCHEMBL18263899 | 0.81 | L3MBTL1 (0.68) | L3MBTL1CYP2C19PKMRAPGEF4HDAC3 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 117 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20150284388-A1 | PROCESSES AND INTERMEDIATES FOR PRODUCING AZAINDOLES | VERTEX PHARMACEUTICALS INCORPORATED | 2015-10-08 | — | — | US | claimed |
| US-20150099884-A1 | PROCESSES AND INTERMEDIATES FOR PRODUCING AZAINDOLES | VERTEX PHARMACEUTICALS INCORPORATED | 2015-04-09 | — | — | US | claimed |
| US-20140309421-A1 | PROCESSES AND INTERMEDIATES FOR PRODUCING AZAINDOLES | VERTEX PHARMACEUTICALS INCORPORATED | 2014-10-16 | — | — | US | claimed |
| EP-2729465-A2 | PROCESSES AND INTERMEDIATES FOR PRODUCING AZAINDOLES | Vertex Pharmaceuticals Incorporated (US) | 2014-05-14 | — | — | EP | claimed |
| US-8513414-B2 | Processes and intermediates for producing azaindoles | VERTEX PHARMACEUTICALS INCORPORATED (US) | 2013-08-20 | — | — | US | claimed |
| US-20130102782-A1 | PROCESSES AND INTERMEDIATES FOR PRODUCING AZAINDOLES | VERTEX PHARMACEUTICALS INCORPORATED (US) | 2013-04-25 | — | — | US | claimed |
| WO-2013006634-A9 | PROCESSES AND INTERMEDIATES FOR PRODUCING AZAINDOLES | VERTEX PHARMACEUTICALS INCORPORATED (US) | 2013-03-21 | — | — | WO | claimed |
| WO-2013006634-A2 | PROCESSES AND INTERMEDIATES FOR PRODUCING AZAINDOLES | VERTEX PHARMACEUTICALS INCORPORATED (US) | 2013-01-10 | — | — | WO | claimed |
| US-20250099442-A1 | COMPOUNDS FOR USE IN TREATING NEUROLOGICAL DISORDERS | PROTHENA BIOSCIENCES INC | 2025-03-27 | — | — | US | disclosed |
| US-20240360157-A1 | TYK2 INHIBITORS | BIOGEN MA INC. | 2024-10-31 | — | — | US | disclosed |
| WO-2024087419-A1 | NITROGEN-CONTAINING HETEROCYCLIC BORONIC ACID COMPOUND, AND PREPARATION METHOD THEREFOR AND USE THEREOF | 浙大城市学院 | 2024-05-02 | — | — | WO | disclosed |
| CN-117430589-A | 2-aminopyrimidine compound or salt thereof, and preparation method and application thereof | 励缔(杭州)医药科技有限公司 | 2024-01-23 | — | — | CN | disclosed |
| US-20230416256-A1 | SMALL MOLECULE INHIBITORS OF NF-kB INDUCING KINASE | JANSSEN PHARAMCEUTICA NV (BE) | 2023-12-28 | — | — | US | disclosed |
| CN-113698395-B | Transforming growth factor receptor antagonist, preparation method and application thereof | 赛诺哈勃药业（成都）有限公司 | 2023-12-08 | — | — | CN | disclosed |
| US-20040053931-A1 | Azaindoles | AVENTIS PHARMACEUTICALS INC. | 2004-03-18 | — | — | US | disclosed |
| EP-1397360-A1 | AZAINDOLES | Aventis Pharma Limited (GB) | 2004-03-17 | — | — | EP | disclosed |
| US-20040009983-A1 | Azaindoles | AVENTIS PHARMA LIMITED (GB) | 2004-01-15 | — | — | US | disclosed |
| WO-2003000688-A1 | AZAINDOLES | AVENTIS PHARMA LIMITED (GB) | 2003-01-03 | — | — | WO | disclosed |
| EP-1263759-A2 | AZAINDOLES | Aventis Pharma Limited (GB) | 2002-12-11 | — | — | EP | disclosed |
| WO-2001047922-A2 | AZAINDOLES | AVENTIS PHARMA LIMITED (GB) | 2001-07-05 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (9 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20040053931-A1 | Azaindoles | CDKN1A, CDK7, CDK2 | L3MBTL1 4557/4885CYP2C19 110/4885PKM 518/4885 |
| US-20150099884-A1 | PROCESSES AND INTERMEDIATES FOR PRODUCING AZAINDOLES | JAK2, JAK3, JAK1 | L3MBTL1 4344/4885CYP2C19 552/4885PKM 947/4885 |
| US-20230416256-A1 | SMALL MOLECULE INHIBITORS OF NF-kB INDUCING KINASE | NFKBIA, IKBKB, NFRKB | L3MBTL1 2176/4885CYP2C19 4079/4885PKM 700/4885 |
| US-20140309421-A1 | PROCESSES AND INTERMEDIATES FOR PRODUCING AZAINDOLES | JAK2, JAK3, JAK1 | L3MBTL1 4344/4885CYP2C19 552/4885PKM 947/4885 |
| US-20250099442-A1 | COMPOUNDS FOR USE IN TREATING NEUROLOGICAL DISORDERS | DYRK2, DYRK1A, DYRK1B | L3MBTL1 3232/4885CYP2C19 3497/4885PKM 320/4885 |
| US-20040009983-A1 | Azaindoles | CCNY, CCNO, CKS2 | L3MBTL1 2911/4885CYP2C19 983/4885PKM 3503/4885 |
| US-20130102782-A1 | PROCESSES AND INTERMEDIATES FOR PRODUCING AZAINDOLES | JAK2, JAK3, JAK1 | L3MBTL1 4344/4885CYP2C19 552/4885PKM 947/4885 |
| US-20240360157-A1 | TYK2 INHIBITORS | TYK2, JAK2, ABL1 | L3MBTL1 2688/4885CYP2C19 1888/4885PKM 772/4885 |
| US-20150284388-A1 | PROCESSES AND INTERMEDIATES FOR PRODUCING AZAINDOLES | JAK2, JAK3, JAK1 | L3MBTL1 4344/4885CYP2C19 552/4885PKM 947/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.